Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VORASIDENIB for Malignant oligodendroglioma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where VORASIDENIB was used for Malignant oligodendroglioma.

Most Reported Side Effects for VORASIDENIB

Side Effect Reports % Deaths Hosp.
Alanine aminotransferase increased 33 12.5% 0 5
Fatigue 27 10.2% 1 2
Aspartate aminotransferase increased 26 9.9% 0 5
Malignant neoplasm progression 25 9.5% 2 3
Seizure 21 8.0% 0 5
Hepatic cytolysis 18 6.8% 0 0
Headache 17 6.4% 0 1
Hepatic enzyme increased 17 6.4% 0 1
Gamma-glutamyltransferase increased 16 6.1% 0 2
Nausea 16 6.1% 1 2
Hepatotoxicity 13 4.9% 0 1
Diarrhoea 12 4.6% 0 1
Drug-induced liver injury 10 3.8% 0 6
Dizziness 9 3.4% 0 2
Fall 8 3.0% 0 2

Other Indications for VORASIDENIB

Brain neoplasm malignant (83) Astrocytoma (42) Product used for unknown indication (40) Oligodendroglioma (34) Glioma (26) Brain neoplasm (20)

Other Drugs Used for Malignant oligodendroglioma

TEMOZOLOMIDE (40) VINCRISTINE (11) BEVACIZUMAB (10) PROCARBAZINE (9) LOMUSTINE (7) OLAPARIB (7) PEMBROLIZUMAB (5)

Related Pages

VORASIDENIB Full Profile All Malignant oligodendroglioma Drugs VORASIDENIB Demographics VORASIDENIB Timeline